Cabot (NYSE:CBT - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 7.150-7.500 for the period, compared to the consensus earnings per share estimate of 7.300. The company issued revenue guidance of -.
Cabot Stock Up 1.5%
Shares of CBT traded up $1.16 during trading hours on Friday, hitting $78.90. The company had a trading volume of 71,987 shares, compared to its average volume of 429,283. The firm has a fifty day moving average price of $75.91 and a 200-day moving average price of $79.62. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.30 and a current ratio of 2.13. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of 10.32 and a beta of 0.87. Cabot has a 52-week low of $70.40 and a 52-week high of $117.46.
Cabot (NYSE:CBT - Get Free Report) last issued its earnings results on Monday, August 4th. The specialty chemicals company reported $1.90 earnings per share for the quarter, topping analysts' consensus estimates of $1.80 by $0.10. Cabot had a return on equity of 25.68% and a net margin of 11.14%. The business had revenue of $923.00 million during the quarter, compared to analyst estimates of $957.29 million. On average, equities research analysts forecast that Cabot will post 7.57 EPS for the current fiscal year.
Cabot Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 29th will be given a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 2.3%. Cabot's dividend payout ratio (DPR) is 23.53%.
Analysts Set New Price Targets
A number of research firms have issued reports on CBT. UBS Group set a $82.00 price target on Cabot and gave the company a "neutral" rating in a research note on Tuesday. Wall Street Zen lowered Cabot from a "buy" rating to a "hold" rating in a report on Wednesday, May 7th.
View Our Latest Research Report on Cabot
Institutional Investors Weigh In On Cabot
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CBT. Acadian Asset Management LLC purchased a new position in Cabot during the first quarter valued at approximately $96,000. Geneos Wealth Management Inc. raised its holdings in shares of Cabot by 409.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company's stock valued at $38,000 after buying an additional 364 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cabot by 3.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company's stock valued at $10,145,000 after buying an additional 4,048 shares during the period. Empowered Funds LLC raised its holdings in shares of Cabot by 102.6% in the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company's stock valued at $2,341,000 after buying an additional 14,260 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company's stock worth $36,802,000 after purchasing an additional 108,645 shares during the period. 93.18% of the stock is currently owned by hedge funds and other institutional investors.
About Cabot
(
Get Free Report)
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Recommended Stories
Before you consider Cabot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.
While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.